The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Metastatic malignant melanoma (MMM) is a highly aggressive disease. Immune checkpoint inhibitors have proved immunotherapeutic efficacy; however, not all patients profit and severe side effects may occur. Currently, little is known about the tumour-specific targets and the tumour-reactive effector cells that are involved. Aiming to characterise the melanoma immune-peptidome, we purified HLA-I and...